IAVI Acquires Aeras TB Vaccine Clinical Programs and Assets

01/10/2018

Published: Oct 01, 2018

NEW YORK, Oct. 1, 2018 /PRNewswire/ — The International AIDS Vaccine Initiative (IAVI) and Aeras, a nonprofit organization dedicated to developing tuberculosis (TB) vaccines, today announced the transfer to IAVI of Aeras’ TB vaccine clinical research programs and assets, consisting of certain clinical staff, clinical programs, biorepository, funding commitments, and other assets.

(PRNewsfoto/International AIDS Vaccine Init)

The transaction, effective today, will enable the continuity of Aeras’ core TB vaccine clinical programs and will expand IAVI’s clinical development capabilities and network, incorporating an experienced clinical team and South African clinical partner network with a strong track record in later-stage clinical trials and work with adolescent and adult populations.

https://www.biospace.com/article/releases/iavi-acquires-aeras-tb-vaccine-clinical-programs-and-assets/?TrackID=21